SCHEMBL14949266

SCHEMBL14949266

CCOc1nc(N)cc(Oc2ccc(-c3nnc(Nc4cccc(C)c4)[nH]3)cc2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.40
KIT P10721 1/20 0.40
PDGFRA P16234 1/20 0.40
CDK11B P21127 1/20 0.40
FLT3 P36888 1/20 0.40
CDKL2 Q92772 1/20 0.40
SCN2A Q99250 1/20 0.35
SCN10A Q9Y5Y9 1/20 0.35
CDK8 P49336 2/20 0.34
MAPT P10636 2/20 0.33
TP53 P04637 1/20 0.33
KDR P35968 2/20 0.33
TNNI3K Q59H18 1/20 0.33
SYK P43405 1/20 0.33
AURKB Q96GD4 1/20 0.33
TTBK1 Q5TCY1 1/20 0.32
TTBK2 Q6IQ55 1/20 0.32
POLB P06746 1/20 0.32
ABL1 P00519 1/20 0.31
EGFR P00533 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14949356 0.92 CDK8 (0.34) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL12336296 0.92 CHKA (0.35) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949291 0.91 KIT (0.38) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL12336257 0.90 PDGFRB (0.39) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949696 0.90 PDGFRB (0.41) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL626064 0.89 PDGFRB (0.53) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL12336247 0.88 PDGFRB (0.35) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949274 0.87 PDGFRB (0.41) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949247 0.87 RAB9A (0.37) PDGFRBKITPDGFRACDK11BFLT3
SCHEMBL14949258 0.87 PDGFRB (0.43) PDGFRBKITPDGFRACDK11BFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2016-04-07 US disclosed
US-9212151-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-12-15 US disclosed
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. 2015-06-11 US disclosed
US-8957216-B2 Heterocyclic compounds useful for kinase inhibition AMITECH THERAPEUTIC SOLUTIONS, INC. (US) 2015-02-17 US disclosed
US-20130266636-A1 METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-10-10 US disclosed
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION AMITECH THERAPEUTIC SOLUTIONS INC (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123284-A1 HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885
US-20150158828-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885
US-20160096824-A1 Heterocyclic Compounds Useful for Kinase Inhibition MAP4K2, MAP3K20, MAP3K19 PDGFRB 497/4885KIT 540/4885PDGFRA 498/4885
US-20130266636-A1 METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION BRAF, BUB1B, MKI67 PDGFRB 1405/4885KIT 1806/4885PDGFRA 1972/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.